Abbvie Inc. Common Stock (ABBV) 59.62 $ABBV Pioneer

New Post Public Reply Private Reply Replies (0) Message Board

Mar 3, 2015 at 7:45 PM

Abbvie Inc. Common Stock (ABBV) 59.62 $ABBV

Pioneer Fundamental Growth Fund: Why Is It Revving Up?
at Investor's Business Daily - 55 mins ago
Stock mutual fund managers Andrew Acheson and Paul Cloonan have been kicking it into a higher gear at Pioneer Fundamental Growth Fund. The 16.61% average annual return of their $2.4 billion fund ranked in the top 27% of its large-cap growth rivals...
SBUX: 94.00 (-0.22), ESRX: 84.35 (-0.58), LNKD: 265.54 (-3.88), GILD: 102.79 (-1.04), ABBV: 59.62 (-0.84), AAPL: 129.36 (+0.27), CELG: 118.47 (-1.84)

Amgen: The Best Biotech Stock You Don't Own
Dan Strack - at Seeking Alpha - 2 hrs 40 mins ago

BIIB: 412.79 (-3.00), GILD: 102.79 (-1.04), PFE: 34.56 (-0.21), MRK: 58.34 (-0.24), AMGN: 158.56 (-1.07), ABBV: 59.62 (-0.84), GSK: 47.71 (-0.22), BMY: 61.92 (-0.38), HSP: 87.71 (+0.04), NVS: 99.06 (-1.01), CELG: 118.47 (-1.84)

10 Dandy Dividend Healthcare Dogs Hail 14% February Upsides
Fredrik Arnold - at Seeking Alpha - Tue Mar 03, 5:28AM CST

KND: 22.09 (+0.15), VIVO: 20.00 (-0.04), PETS: 15.13 (-0.32), PFE: 34.56 (-0.21), AMGN: 158.56 (-1.07), GSK: 47.71 (-0.22), MSA: 49.71 (-0.47), PDLI: 7.02 (+0.01), BAX: 69.42 (-0.54), AZN: 68.28 (-0.45), MRK: 58.34 (-0.24), STJ: 67.60 (-0.76), TRIB: 18.43 (+0.46), TEVA: 56.46 (-0.70), ABBV: 59.62 (-0.84), THRX: 19.56 (+0.34), SNY: 48.08 (-0.21)

The Dividend House DGI Portfolio: The Good, The Bad, And The Ugly
Dividend House - at Seeking Alpha - Mon Mar 02, 11:51PM CST

KMI: 41.09 (+0.26), ABT: 47.09 (-0.13), HAS: 62.72 (-0.43), GE: 25.86 (-0.25), MAIN: 31.23 (+0.15), HTGC: 14.48 (-1.02), TCAP: 24.53 (+0.25), DLR: 66.72 (-0.22), PFE: 34.56 (-0.21), WMT: 83.37 (-0.59), WFC: 55.45 (-0.10), UL: 44.05 (-0.15), O: 50.55 (-0.10), BMY: 61.92 (-0.38), VOD: 34.62 (+0.04), DEO: 117.22 (-0.54), TUP: 71.11 (-0.50), WTR: 26.45 (+0.07), WBA: 83.21 (-0.41), CBRL: 151.76 (+1.33), MAT: 26.90 (+0.34), OHI: 40.26 (-0.28), ABBV: 59.62 (-0.84), AFL: 62.28 (-0.29), BBL: 49.30 (-0.10), CMCSA: 59.96 (+0.09), OMI: 35.33 (-0.55)

Is Now The Time To Pounce On The Pot Business?
Nicholas Kitonyi - at Seeking Alpha - Mon Mar 02, 2:09PM CST

GWPH: 79.55 (-0.73), ABBV: 59.62 (-0.84), BMY: 61.92 (-0.38)

Bristol Myers' HCV Cocktail Has Gilead, AbbVie In Its Crosshairs
Shock Exchange - at Seeking Alpha - Mon Mar 02, 9:32AM CST

GILD: 102.79 (-1.04), ABBV: 59.62 (-0.84), BMY: 61.92 (-0.38)

These Stocks Just Raised Their Dividends
Eric Volkman, The Motley Fool - Motley Fool - Mon Mar 02, 7:03AM CST
With all the dividend raises occurring in this early part of the year, several likely suspects have decided to get in on the action. These are the Dividend Aristocrats, the companies that have raised their distributions at least once annually for a...
KO: 42.95 (-0.25), ABT: 47.09 (-0.13), ABBV: 59.62 (-0.84), CL: 70.68 (-0.33)

Billionaire George Soros Just Dumped These 3 Dividend Stocks
George Budwell, The Motley Fool - Motley Fool - Sun Mar 01, 9:55AM CST
Because billionaire investors can have a disproportionately large impact on how markets behave in the short term, their buys and sells tend to be closely scrutinized. And controversial hedge-fund manager George Soros is one of the most widely watched...
GILD: 102.79 (-1.04), MRK: 58.34 (-0.24), AZN: 68.28 (-0.45), TEVA: 56.46 (-0.70), ABBV: 59.62 (-0.84)

Achillion: The Dark Side
Kanak Kanti De - at Seeking Alpha - Fri Feb 27, 5:45AM CST

GILD: 102.79 (-1.04), ACHN: 12.14 (-0.21), ABBV: 59.62 (-0.84)

Cyberonics Soars On Earnings Beat, Tax Inversion Deal
at Investor's Business Daily - Thu Feb 26, 12:58PM CST
Shares of Cyberonics (CYBX) gapped up to a record high Thursday after the company reported better than expected earnings growth and said it is merging with Italy's Sorin and moving its headquarters to Europe despite new Treasury rules intended to...
ABMD: 60.15 (-2.04), QSR: 43.62 (-1.05), MDT: 78.03 (-0.80), BAX: 69.42 (-0.54), SHPG: 238.90 (+2.48), EW: 134.58 (-1.27), ABBV: 59.62 (-0.84), CYBX: 70.36 (+0.21)

Biotech Head-to-Head: Gilead vs. Celgene
Todd Campbell and Michael Douglass, The Motley Fool - Motley Fool - Thu Feb 26, 11:03AM CST
It's Fool versus Fool on this health care edition of Industry Focus. Michael Douglass argues for Gilead Sciences , while Todd Campbell goes to bat for Celgene . Which of these biotech giants is the better investment? Both companies have had...
GILD: 102.79 (-1.04), ABBV: 59.62 (-0.84), CELG: 118.47 (-1.84)

Cyberonics, Sorin Plan to Merge in Latest Tax Inversion Deal
at The Street - Thu Feb 26, 10:54AM CST
Medical device manufacturers Cyberonics and Sorin will join forces and move their headquarters to the U.K. in a deal propelled by the search for lower corporate taxes.
SHPG: 238.90 (+2.48), ABBV: 59.62 (-0.84), CYBX: 70.36 (+0.21)

New Parkinson's drug cleared in Europe
Seeking Alpha - at Seeking Alpha - Thu Feb 26, 9:23AM CST

ADMS: 17.25 (-0.05), ACOR: 35.20 (+0.19), NDRM: 12.48 (-0.71), XNPT: 7.10 (-0.02), IPXL: 39.93 (-0.52), ABBV: 59.62 (-0.84), TEVA: 56.46 (-0.70), SNY: 48.08 (-0.21), PRTA: 25.63 (-0.84)

FDA accepts Teva's NDA for abuse-deterrent opioid
Seeking Alpha - at Seeking Alpha - Wed Feb 25, 8:42AM CST

MNK: 114.85 (-3.97), LCI: 62.27 (-0.65), ACT: 296.23 (-1.08), EGLT: 15.36 (+0.03), ZGNX: 1.67 (-0.02), PFE: 34.56 (-0.21), ABBV: 59.62 (-0.84), TEVA: 56.46 (-0.70), ALKS: 72.80 (+1.33), ACUR: 0.82 (-0.06)

Updating My Price Target On Gilead Sciences
Alexander J. Poulos - at Seeking Alpha - Tue Feb 24, 12:41PM CST

JNJ: 102.34 (-0.88), ESRX: 84.35 (-0.58), GILD: 102.79 (-1.04), PFE: 34.56 (-0.21), MRK: 58.34 (-0.24), ABBV: 59.62 (-0.84)

Express Scripts Earnings Set the Stage for Growth
Todd Campbell, The Motley Fool - Motley Fool - Tue Feb 24, 10:19AM CST
Source: Express Scripts. As healthcare payers hunt for ways to rein in ever-higher drug costs, the pharmacy benefit manager Goliath Express Scripts Holding Company reported better-than-expected fourth-quarter results, and full year 2014...
ESRX: 84.35 (-0.58), UNH: 112.86 (-1.54), ABBV: 59.62 (-0.84)

AbbVie: Attractive Valuation, Growth Prospects & Yield
Bret Jensen - at Seeking Alpha - Tue Feb 24, 8:39AM CST

ABBV: 59.62 (-0.84)

Gilead: All Is Still Well Down On The Farm
Shock Exchange - at Seeking Alpha - Tue Feb 24, 7:44AM CST

GILD: 102.79 (-1.04), ABBV: 59.62 (-0.84)

Can-Fite's A3AR Biomarker Targets Patients For Highest Efficacy In Phase III Trial
Sharon di Stefano - Seeking Alpha - Tue Feb 24, 7:40AM CST
Rheumatology, a sub-specialty of internal medicine, deals with problems in joints, soft and connective tissue, inflammation of blood vessels and autoimmune disease. Due to the last category and because it underlies the occurrence of rheumatoid...
CANF: 4.50 (-0.15), JNJ: 102.34 (-0.88), AMGN: 158.56 (-1.07), ABBV: 59.62 (-0.84)

Abbvie's 'One Trick Pony' Faces Patent Expiration In 2016
Shock Exchange - at Seeking Alpha - Tue Feb 24, 7:21AM CST

GILD: 102.79 (-1.04), ABBV: 59.62 (-0.84)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

DCM Services Teams with AKUVO to Boost Estate Recoveries

Revolutionizing Estate Recovery Practices Here's the scoop: DCM Services (DCMS), that big shot in estate account resolution, is hooking up with AKUVO to shake up how credit unions handle estate recoveries. This alliance is a clear nod to modernizing a process stuck in the past. Let’s face it, handling decedent and probate accounts is no cakewalk, and traditional methods...

Lick the Plate Hits 2,000 Shows with Clown Band

They say good things come in bizarre packages, and that's exactly the case as David Boylan's Lick the Plate zany celebration marks 15 years on air with its 2,000th episode. If you think of radio as a predictable endeavor, well, you're not tuned into Lick the Plate. A Milepost Draped in Multicolored Fabrics When you're browsing through colorful avenues of radio fame, it's...

Intus Bio Secures $2.7M for Colorectal Cancer Test

Pioneering Efforts in Early-Onset Colorectal Cancer Detection The battlefield of colorectal cancer prevention just got a serious upgrade with Intus Bio grabbing a $2.7 million award. This ain't just pocket change—it's a shot at rewriting the script on how we approach early-onset colorectal cancer, the pesky number one cancer gnawing at the under-50 crowd. Partnering...

Oil Markets Shift Focus: Pipelines Trump Drilling

Decoupling Oil Price and Production Response This oil market isn’t your usual rodeo. With Brent flirting with $100, it’s a seismic shift that’s not yielding new drills but redirecting capital to the existing infrastructure landscape. Ask yourself why we're not seeing the usual cavalry charge of new rigs. It’s simple: Pipeline mileage and producing wells have...

2026 Buy-Side Index Reveals State Market Variance

Toss out your one-size-fits-all real estate predictions; the Q2 2026 Buy-Side Index just unveiled some real whoppers about the housing market. What we're seeing isn't your typical year-over-year growth across the board. Nope, we're seeing splits as sharp as a knife between states. Some places are shooting up in price, while others seem to be stuck in mud. Price Surges and...

Fermi's Founder Pushes for Board Overhaul: What's Next?

Fermi's Roller Coaster: A Founder’s Stand Seems like Fermi Inc. is on a wild ride through the business landscape, and it's giving shareholders more whiplash than satisfaction these days. Toby Neugebauer, co-founder of Fermi and the loudest voice in the room, is feeling like his company is facing some serious turbulence and seems determined not to sit idly by as it hits...

NYSE Reflects on 9/11: Honoring Lives and Legacy

A Somber Day at NYSE: Reflecting on 9/11 September 11th grips the heart of NYSE every year, but this year's 25th-anniversary powerfully reverberates through its hallowed halls. The hustle of the trading floor halts for a moment at 9:20 AM ET, paying homage to those lost in the harrowing attacks. I've seen the markets flap in the wind of countless crises, but nothing's...

Sustainability Investments: $17 Trillion Wager Faces Divergence

Sustainability Investments: A Tale of Contrasts In the world of sustainability, a staggering $17 trillion has been poured into technologies over the past decade. That’s no chump change. But what do we have to show for it? According to Bain & Company’s latest report, this massive financial injection hasn’t exactly hit a home run. Progress, much like the stock market...

Americas Cardroom's Poker Series Hits $7.2M Haul

Massive Prize Pools Emerge in Just Four Days I found myself eyeballing some jaw-dropping numbers from Americas Cardroom's latest poker series, the Online Super Series XL. It's not every day you see nearly a hundred tournaments rake in over $7.2 million in prize pools in just four days. From September 6th to 9th, a whopping 62,847 entries signed up to make an honest...

Modeling and Mental Health Join Forces for Wellness

A Fresh Alliance for Mental Wellness in Modeling Alright, let's shine a spotlight on a significant step in the modeling industry, a place typically less vocal about mental health. In a move that feels long overdue, Brain-Body Therapy and Mother Model Management have joined forces, marking the beginning of a collaborative effort to propel mental wellness to the forefront...